How to obtain the most effective results when treating chronic hepatitis C virus?;Comment obtenir une efficacité maximale du traitement actuel de l'hépatite chronique virale C?

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 6-7, 2007, Pages 573-577

  Ouzan, Denis ^a  

^a INSTITUT ARNAULT TZANCK   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

GENOTYPE; HEPATITIS C; HUMAN; REVIEW; SENSITIVITY ANALYSIS; THERAPY EFFECT; VIROLOGY;

EID: 34447634914     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)89433-4     Document Type: Article

References (31)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
3. Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
4. Halfon P, Penaranda G, Bourliere M, Khiri H, Masseyeff MF, Ouzan D. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection. J Med Virol 2006;78: 208-15.
5. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
6. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:1438-47.
7. Boulestin A, Kamar N, Sandres-Saune K, Legrand-Abravanel F, Alric L, Vinel JP et al. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J Med Virol 2006;78:365-71.
8. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peg interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
9. Tang KH, Herrmann E, Cooksley H, Tatman N, Chokshi S, Williams R et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol 2005;43:776-82.
10. Ouzan D, Khiri H, Penaranda G, Joly H, Halfon P. Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients. Comp Hepatol 2005;21:4-9.
11. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006;44:360-367.
12. Gerotto M, Dal Pero F, Bortoletto G, Ferrari A, Pistis R, Sebastiani G et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006;44:83-7.
13. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003;39: 106-111.
14. Shiffman M, Pappas S, Nyberg L, Greenbloom S, Gibas A, Bacon B et al. Peginterferon alpha-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the accelerate trial. J Hepatol 2006;44 (Suppl 2):S271.
15. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
16. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-17.
17. Dalgard O, Bjoro K, Hellum K, Myrvang B, Ritland S, Skaug K et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
18. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000;182:28-35.
19. Zeuzem S, Fried MW, Reddy R, Marcellin P, Diago M, Craxi A et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response in patient infected with hepatitis C genotype 1 treated with peg interferon alpha 2a plus ribavirin. Hepatology 2006;44:267A.
20. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr. et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
21. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon-alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004;189:964-70
22. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr. et al Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
23. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhances sustained response in genotype-1-Infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-69.
24. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa 2a plus ribavirin. Gastroenterology 2006;131:1040-48.
25. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
26. Sanchez-Tapias J, Diago M, Escartin P, Enrequez J, Moreno R, Romero-Gomez M et al. Peginterferon alpha 2a plus ribavirin for 72 weeks in chronic hepatitis C patients without a response by week 4. Gastroenterology 2006;131:451-60.
27. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia. J Hepatol 2006;44:97-103.
28. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60.
29. DiagoM, Romeo-Gomez M, Crespo, Olveira A, Perez R, Barcena R et al. Peg interferon Alfa 2a plus ribavirin in patients infected with HCVgenotype1who failed to repond to interferon and ribavirin final results of the Spanish high-dose induction pilot trial Hepatology 2004;40:389A.
30. Gross J, Johnson S, Kwo P, Afdhal N, Flamm S, Themeau T. Double dose peg interferon alfa 2b with weight-based ribavirin improves response for interferon/ribavirin non responders with hepatitis C: final results of RENEW. Hepatology 2005;42:A60.
31. Pawlotsky JM. Nouvelles stratégies thérapeutiques dans l'hépatite chronique C. Gastroenterol Clin Biol 2006;30:1009-11.